A double-blind, placebo-controlled, randomized efficacy and safety study of levetiracetam extended release formulation (LEV XR), administered as 2 x 500 mg LEV XR tablets once daily as add-on therapy in subjects from 12 to 70 years with refractory epilepsy suffering from partial onset seizures.

Trial Profile

A double-blind, placebo-controlled, randomized efficacy and safety study of levetiracetam extended release formulation (LEV XR), administered as 2 x 500 mg LEV XR tablets once daily as add-on therapy in subjects from 12 to 70 years with refractory epilepsy suffering from partial onset seizures.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2014

At a glance

  • Drugs Levetiracetam (Primary)
  • Indications Epilepsy; Partial epilepsies
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors UCB
  • Most Recent Events

    • 12 Jul 2011 Actual end date changed from May 2007 to Jul 2007 as reported by European Clinical Trials Database.
    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database record, EudraCT2006-000987-10).
    • 05 Dec 2008 Results published in Epilepsia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top